Emma Children's Hospital Academic Medical Centre, Department of Paediatric Respiratory Medicine and Allergy, University of Amsterdam, Amsterdam, Netherlands.
Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands.
Front Immunol. 2018 Mar 29;9:630. doi: 10.3389/fimmu.2018.00630. eCollection 2018.
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in infancy with a complex pathology. In adults, the clinical severity of AD has been associated with increases in T helper cell type (Th) 2, Th22, and Th17 serum markers, including high levels of CC chemokine ligand (CCL) 17 and CCL22 chemokines.
To explore the possible association between serum chemokine levels and AD severity in infants with moderate-to-severe AD and elevated immunoglobulin E (IgE).
Serum samples ( = 41) obtained from a randomized, double-blind, and clinical dietary intervention study were used to study biomarkers in infants with AD. Baseline- and post-intervention samples (4 months) were used, six chemokines and nine ratios thereof were analyzed using Luminex and correlated to AD severity. In the initial study, the infants were randomized to receive extensively hydrolyzed whey-based formula without (control) or with short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and M-16V (active).
31 Infants up to 11 months of age, with an objective-SCORAD score (oSCORAD) ≥ 20 and elevated total-IgE and/or specific-IgE levels were included. In time, the median oSCORAD decreased in both groups by -8 (control, < 0.05; active, < 0.01). Irrespective of dietary intervention, several changes in Th2 chemokines (CCL17 and CCL22), inflammatory chemokine (CCL20), and the Th1 chemokine, CXC chemokine ligand (CXCL) 9, were detected over time. Overall CCL17 correlated to oSCORAD ( = 0.446, < 0.01). After 4 months of dietary intervention, CXCL9 was higher ( < 0.01) in the active group compared with control [active, 2.33 (1.99-2.89); controls, 1.95 (1.77-2.43) log 10 median (range)]. In addition, a reduction in Th2/Th1 chemokine ratios for CCL17/CXCL9, CCL22/CXCL9, CCL20/CXCL10, and CCL20/CXCL11 was detected associated with the active intervention.
While this study is small and exploratory in nature, these data contribute to immune biomarker profiling and understanding of AD in infants.
特应性皮炎（AD）是婴儿期最常见的慢性炎症性皮肤病，其发病机制复杂。在成年人中，AD 的临床严重程度与辅助性 T 细胞（Th）2、Th22 和 Th17 血清标志物的增加有关，包括趋化因子配体（CC）17 和 CCL22 趋化因子的高水平。
探索中度至重度特应性皮炎婴儿的血清趋化因子水平与 AD 严重程度之间的可能关联，这些婴儿的免疫球蛋白 E（IgE）升高。
本研究使用来自一项随机、双盲、临床饮食干预研究的血清样本，研究 AD 婴儿的生物标志物。使用基线和干预后（4 个月）样本，使用 Luminex 分析了 6 种趋化因子及其 9 种比值，并与 AD 严重程度相关。在初始研究中，将婴儿随机分为接受不含（对照）或含短链半乳糖/长链果糖（9:1）和 M-16V 的深度水解乳清基配方，以及活性组。
共纳入 31 名年龄在 11 个月以下的婴儿，其客观 SCORAD（oSCORAD）评分（oSCORAD）≥20 且总 IgE 和/或特异性 IgE 水平升高。随着时间的推移，两组的中位数 oSCORAD 均下降（对照组，<0.05；活性组，<0.01）。无论饮食干预如何，均发现 Th2 趋化因子（CCL17 和 CCL22）、炎症趋化因子（CCL20）和 Th1 趋化因子 CXC 趋化因子配体（CXCL）9 随时间发生了变化。总体而言，CCL17 与 oSCORAD 相关（=0.446，<0.01）。经过 4 个月的饮食干预，与对照组相比，活性组的 CXCL9 更高（<0.01）[活性组，2.33（1.99-2.89）；对照组，1.95（1.77-2.43）log10 中位数（范围）]。此外，还检测到 CCL17/CXCL9、CCL22/CXCL9、CCL20/CXCL10 和 CCL20/CXCL11 的 Th2/Th1 趋化因子比值降低，与活性干预有关。
尽管本研究的性质是小规模和探索性的，但这些数据有助于免疫生物标志物的分析和婴儿 AD 的发病机制的理解。
Zotero 插件
